delapril hcl

Modify Date: 2025-08-25 20:43:31

delapril hcl structure	Common Name	delapril hcl
	CAS Number	83435-67-0	Molecular Weight	489.004
	Density	N/A	Boiling Point	659.7ºC at 760 mmHg
	Molecular Formula	C₂₆H₃₃ClN₂O₅	Melting Point	169ºC
	MSDS	N/A	Flash Point	352.7ºC

Use of delapril hcl

Delapril is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases[1].

Name	Delapril Hydrochloride
Synonym	More Synonyms

Description	Delapril is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)
Target	ACE[1]
In Vivo	Delapril (3 mg/kg; administered orally for 2 weeks) exerts potent ACE inhibitory activity in spontaneously hypertensive rat (SHR) [1]. Delapril (1-10 mg/kg; orally) exerts a marked and long-lasting antihypertensive action in various experimental models of hypertension[1]. Animal Model: SHR[1] Dosage: 3 mg/kg Administration: Administered orally; 2 weeks Result: Exerted potent ACE inhibitory activity. Animal Model: 2-kidney, 1-clip hypertensive Rats, Dogs, and SHR[1] Dosage: 1-10 mg/kg Administration: Oral Result: Exerted a marked and long-lasting antihypertensive action.
References	[1]. Razzetti R, et al. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol. 1995 Jun 16;75(18):7F-12F.

Boiling Point	659.7ºC at 760 mmHg
Melting Point	169ºC
Molecular Formula	C₂₆H₃₃ClN₂O₅
Molecular Weight	489.004
Flash Point	352.7ºC
Exact Mass	488.207794
PSA	95.94000
LogP	3.80250
InChIKey	FDJCVHVKXFIEPJ-JCNFZFLDSA-N
SMILES	CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1.Cl

delapril hcl MSDS(Chinese)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MB9668000

CHEMICAL NAME :: Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-(N-(1-(ethoxycarbonyl )-3-phenylpropyl)-L-a lanyl)-, monohydrochloride, (S)-

CAS REGISTRY NUMBER :: 83435-67-0

LAST UPDATED :: 199206

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C26-H32-N2-O5.Cl-H

MOLECULAR WEIGHT :: 489.06

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 8260 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 208 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5900 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3120 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 164 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2340 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 27300 mg/kg/13W-C

TOXIC EFFECTS :: Blood - changes in leukocyte (WBC) count

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),31,1987 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 8700 mg/kg

SEX/DURATION :: female 15-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

(S)-2-[(S)-1-[N...

CAS#:83435-61-4

~92%

delapril hcl

CAS#:83435-67-0

Literature: Takeda Chemical Industries, Ltd. Patent: US4835302 A1, 1989 ;

sodium (indan-2...

CAS#:1001015-87-7

Ethyl (S)-2-[(S...

CAS#:84793-24-8

~91%

delapril hcl

CAS#:83435-67-0

Literature: DIPHARMA FRANCIS s.r.l. Patent: US2008/15383 A1, 2008 ; Location in patent: Page/Page column 3 ;

N-[N-[(S)-1-eth...

CAS#:83435-62-5

~71%

delapril hcl

CAS#:83435-67-0

Literature: Miyake; Itoh; Oka Chemical and Pharmaceutical Bulletin, 1986 , vol. 34, # 7 p. 2852 - 2858

Ethyl 2-oxo-4-p...

CAS#:64920-29-2

delapril hcl

CAS#:83435-67-0